Navigation Links
Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
Date:3/23/2009

TORONTO, March 23 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX:TTH) announced today that the first patient has been dosed in a clinical study of gastrin analogue TT-223 in combination with a proprietary Lilly GLP-1 analogue, in patients with type 2 diabetes. The study is a randomized, double-blind, placebo-controlled study in approximately 140 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations of GLP-1 analogue, for a combination treatment period of 4 weeks with a 5-month follow-up.

For information on enrollment, patients or caregivers can visit the website www.clinicaltrials.gov under study # NCT00853151

    About Gastrin-Based Therapies
    -----------------------------

Transition and Eli Lilly and Company (NYSE: LLY) have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize gastrin based therapies, including the lead compound TT-223. Gastrin based therapies are an emerging class of potential disease-modifying therapies for patients with diabetes, and have been shown to provide sustained improvement in glycemic control in preclinical models and early clinical studies. Sustained improvement in glycemic control is a key goal for patients with diabetes in order to alleviate the symptoms of hyperglycemia and to prevent diabetic complications, and improving their overall quality of life.

    About Transition
    ----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large marke
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Mylan Announces Transition of Chief Financial Officer
2. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
3. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
4. CDS Completes Large-Scale Transition of Medicare Data Processing
5. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
6. Is rapid transition through menopause linked to earlier onset of heart disease?
7. MEDai Presents on Transitioning Predictive Modeling Integration From Care Management to Actuarial Applications
8. Mental Health Leaders Meet with Transition Team
9. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
10. AUDIO from Medialink and Transitions Optical: New Years Resolutions for Healthier Eyes
11. Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oct. 30, 2014 (HealthDay News) -- The number of ... sharply since 2002, according to a new study. ... most doctors remained flat or declined in recent years, ... of the American Medical Association . "For many ... is a disturbing aspect of modern clinical practice," researchers, ...
(Date:10/31/2014)... — A new report by Milken Institute School ... George Washington University examines the challenge of maintaining ... enrolled in Covered California and who are also ... Services Program (CPSP). The CPSP, whose roots are ... ever developed for low-income pregnant women, makes enriched ...
(Date:10/30/2014)... could one day provide new treatments for injuries and ... ligaments. , Cartilage, for example, is a hard material ... to work smoothly. UC Davis biomedical engineers, exploring ways ... strong outside the body, report new developments this week ... of Sciences . , "The problem with engineered tissue ...
(Date:10/30/2014)... and her research group at the DFG Research Center ... the TU Dresden (CRTD) demonstrated for the first time ... cord in three dimensions from mouse embryonic stem cells. ... interneurons along the dorsal/ventral axis was observed., This study ... " Stem Cell Reports " on 30.10.2014 ., For ...
(Date:10/30/2014)... 2014 Timothy, InstaKNOT’s 4-year-old ... firefighters, showing that you are never too young to ... firefighters Tracey and Carl at the 2013 Santa Arriving ... Pompano Beach Chamber of Commerce. Tracey gave Timothy a ... Timothy wear his real fireman’s hat, and extending an ...
Breaking Medicine News(10 mins):Health News:Fewer Malpractice Claims Paid in U.S. 2Health News:Report examines health care challenges for pregnant women enrolled in covered California 2Health News:Making lab-grown tissues stronger 2Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4
... Center have established that an individual’s health and ... interplay between genetic and environmental factors//. In addition, ... the psychological and biological response to a stressful ... studies that examined the genetic-environment association were presented ...
... 70 % minimum requirement in the HSC examinations is necessary ... and dental colleges in the open category. ,Chief ... for admission in medical and dental colleges would be given ... the government said it would be given 40 % weightage. ...
... 400 million hectares of natural grassland, the second biggest in ... has degraded to various extents and hence the Chinese vice ... the country's grasslands. ,He said that grassland is ... , This is mainly done as a part ...
... radiation watchdog in Finland has decided to test the effects ... by testing them directly on human skin in order to ... ,A pilot study that is scheduled to begin sometime ... the participants' arms to cell phone radiation for about 60 ...
... has been helping South Africans to improve their lives by ... in various cities seek to teach// people how to use ... lies between the conscious state and sleep. ,"Even ... percent of their mind power," Adhia told students at workshops ...
... Orissa ostracized a HIV positive woman and her two children, ... in their school//. ,Sanjukta, 34, lost her husband ... daughter have been infected, the younger daughter is healthy, said ... ,Soon after her husband Pradeep Nayak's death in January, residents ...
Cached Medicine News:Health News:Genes And Environmental Factors Determine Stress Response 2
(Date:10/31/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... Pharmaceuticals, Third Quarter 2014 Financial Results and Highlights Conference ... ET / 8:30 a.m. PTWhere: , www.isispharm.com ... onto our website listed above. If you are unable ... the webcast will be available for a limited time ...
(Date:10/30/2014)... -- Stryker Orthopaedics, the Official Joint Replacement Products of ... its debut year of the relationship at the Charles ... This marks the eleventh tournament stop along both ... has activated on-site with the "Stryker Mobility Zone" – ... importance of joint health.  The Stryker ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Electronic ... dramatically as a result of government initiatives and ... - healthcare providers have invested over the past ... heart of health IT, and U.S. clinicians use ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4
... May 25 AcelRx Pharmaceuticals, Inc. today announced ... the safety and efficacy of the ARX-02 Sufentanil NanoTab™ ... breakthrough pain in opioid-tolerant patients. The primary endpoint of ... first 30 minutes after dosing (SPID-30) was highly statistically ...
... town hall meeting a year ago, President Obama said that home-based care could ... of more expensive institutional care.  "I actually think homecare ends up being cost-efficient ... their homes," the president told his audience in the Cleveland suburb ... , , ...
Cached Medicine Technology:AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain 2AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain 3Medicare Policies Ignore Aging-at-Home Concept 2Medicare Policies Ignore Aging-at-Home Concept 3Medicare Policies Ignore Aging-at-Home Concept 4Medicare Policies Ignore Aging-at-Home Concept 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: